The U.S. Food and Drug Administration (FDA) has given a green light to the new Cala kIQ Plus system, Cala Health’s next-generation wearable neurostimulation device for helping control hand tremor during movement in people with Parkinson’s disease. The system is an update of the earlier approved Cala…
News
Amprion is partnering with Macquarie University in Australia to expand access to its SAAmplify-alphaSYN test, which detects abnormal alpha-synuclein protein in people with suspected neurodegenerative diseases. The test can help diagnose Parkinson’s disease early, as well as help identify specific types of…
Researchers at Florida International University (FIU) have identified a compound that boosts the function of mitochondria (cells’ powerhouses) and may slow the progression of Parkinson’s disease. The scientists found that by reducing the activity of a protein called dynamin-related protein 1 (DRP1), which regulates mitochondrial function, the compound, CTS2444-32,…
Bial has launched an international education campaign to support clearer communication and the early identification of symptoms among people with Parkinson’s disease, carers, and healthcare professionals. The year-long campaign, called “Dialogues with Parkinson’s,” is being developed in collaboration with Parkinson’s Europe to mark World Parkinson’s Day,…
Rune Labs has launched StrivePD Guardian, a personalized artificial intelligence (AI) companion tool that helps people with Parkinson’s disease track symptoms and receive support. The system, which pairs the StrivePD app with an Apple Watch, uses extensive real-world clinical data, including wearable-derived data and U.S. Food and…
Levodopa, the gold-standard treatment for Parkinson’s disease, is often given alongside medicines called catechol-O-methyltransferase inhibitors (COMT-Is) that are designed to boost its efficacy — but a new study suggests these medications may also reduce the amount of levodopa available to reach the brain. Specifically, the data suggest treatment with…
A new support group called Angels Embrace aims to offer education, connection, and emotional support for people affected by neurodegenerative conditions such as Parkinson’s disease and dementia. The program is being offered by Angels on Call Homecare, a company recognized for providing specialized Parkinson’s and dementia care at…
A small, lab-made molecule called SK-129 reduced the formation of toxic clumps of the alpha-synuclein protein, a hallmark of Parkinson’s disease, a study found. SK-129 was able to cross the blood-brain barrier – a semipermeable membrane that protects the brain and central nervous system – and prevent damage caused…
In the U.S., the total cost of Parkinson’s disease — including direct medical costs and lost productivity from patients and caregivers — was more than $82 billion in 2024, according to a new report from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The findings build on…
Scientists have demonstrated that it is possible to collect individualized data on how connections among brain circuits change for people with Parkinson’s disease who are undergoing deep brain stimulation (DBS) as a treatment for their symptoms. These findings lay the groundwork for more individualized approaches for DBS, and…
Recent Posts
- Guest Voice: When Parkinson’s disease and bipolar disorder collide
- FDA approves next-gen wearable sensor for tremor control in Parkinson’s
- Amprion working to expand access globally to alpha-synuclein protein test
- When saying no feels like the hardest part of Parkinson’s caregiving
- Researchers ID compound that may slow Parkinson’s progression